Improvements in Plasma Viscosity in Patients with Coronary
Artery Disease
Xingle Ge, Kun Zhao, Taoying
Ding
Xi’an No. 1 Hospital, Xi’an, China, 710002
Abstract: Previous clinical trials have suggested
that CardioPhase can reduce heart muscle ischemia and improve
heart function. Our hospital’s cardiac medical department
observed the clinical therapeutic effects of CardioPhase on
plasma viscosity in 105 patients with coronary artery disease
from May 1993 to October 1994. The results indicate that administration
of CardioPhase can decrease plasma viscosity and reduce the
impact of this contributing factor on the progression of coronary
heart disease and eventual heart infarction.
Patient
Selection
105 patients (70 male, 35 female) with coronary artery disease
were selected for the trial based on WHO diagnostic standards.
Patient ages ranged between 55~70 years, and all presented
with a history of recent angina pectoris attack. Following
hospitalization 45 male patients and 20 female patients were
determined to have elevated plasma viscosity.
Methods
Prior to treatment with CardioPhase we drew 2 mL blood from
each patient on an empty stomach. Analysis was made using
an NEX-1 cone and plate viscometer (Chengdu instrument factory).
The 105 patients in the
study then took 60 g. oral CardioPhase daily for a treatment
course of 40 days.
After the course of treatment
we drew 2 mL blood from each patient, again on an empty stomach.
The results were analyzed by NEX-1 cone and plate viscometer
as before.
The data was divided
into two groups for analysis. The first analysis group consisted
of all patients in the study. The second analysis group contained
the sub-group from the study that had elevated plasma viscosity.
Results
Results of the CardioPhase study are shown in tables 1 and
Table 2.
Group |
n |
Before
Administration |
After
Administration |
P |
Male |
70 |
1.61±0.11 |
1.57±0.05 |
<0.05 |
| Female |
45 |
1.48±0.07 |
1.42±0.11 |
<0.05 |
Table
1. Effect of CardioPhase on plasma viscosity
(mPa-s, ±s). |
Group |
n |
Before
Administration |
After
Administration |
P |
Male |
45 |
1.68±0.14 |
1.59±0.16 |
<0.05 |
| Female |
20 |
1.54±0.13 |
1.42±0.15 |
<0.05 |
Table
2. Effect of CardioPhase on viability of plasma
viscosity for the patients with elevated plasma viscosity
(mPa-s, ±s). |
Discussion
Our results found that after 40 days of treatment
with CardioPhase all patients showed statistically significant
decreases in plasma viscosity. Importantly, the subgroup of
patients with elevated blood viscosity also showed statistically
significant decreases in plasma viscosity. There were no differences
in results with respect to the gender of the participants.
We have shown that CardioPhase
can decrease the plasma viscosity patients with coronary artery
disease.
These results correlate
with the pharmacological actions of CardioPhase. Research
has shown that plasma viscosity is affected by the packing
fractions of karyocytes and by blood esters. The CardioPhase
formula can elevate human karyocyte SOD enzymatic active and
degrade LPO levels in humans. In animal studies it has been
shown to degrade FFA [free fatty acids] and TBA [thiobarbital].
These pharmacological actions are the likely mechanisms that
lead to the reduction in plasma viscosity through the use
of CardioPhase.
Patients with elevated
plasma viscosity have increased likelihood of coronary artery
disease and heart infarction. CardioPhase may prevent the
occurrence and further development of coronary artery disease
and subsequently, heart attack. |
